JP2012533559A - アセトアミノフェンの治療効果を改善するためのｎ−アセチルシステイン組成物および方法 - Google Patents

アセトアミノフェンの治療効果を改善するためのｎ−アセチルシステイン組成物および方法 Download PDF

Info

Publication number
JP2012533559A
JP2012533559A JP2012520791A JP2012520791A JP2012533559A JP 2012533559 A JP2012533559 A JP 2012533559A JP 2012520791 A JP2012520791 A JP 2012520791A JP 2012520791 A JP2012520791 A JP 2012520791A JP 2012533559 A JP2012533559 A JP 2012533559A
Authority
JP
Japan
Prior art keywords
acetaminophen
day
composition
therapeutic effect
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012520791A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012533559A5 (US07981874-20110719-C00313.png
Inventor
レオノーレ エー ハーツェンバーグ
ジェームズ アンドラス
Original Assignee
ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43449800&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2012533559(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ filed Critical ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ
Publication of JP2012533559A publication Critical patent/JP2012533559A/ja
Publication of JP2012533559A5 publication Critical patent/JP2012533559A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2012520791A 2009-07-15 2010-07-15 アセトアミノフェンの治療効果を改善するためのｎ−アセチルシステイン組成物および方法 Pending JP2012533559A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22567909P 2009-07-15 2009-07-15
US61/225,679 2009-07-15
PCT/US2010/042163 WO2011008976A1 (en) 2009-07-15 2010-07-15 N-acetyl cysteine compositions and methods to improved the therapeutic efficacy of acetaminophen

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015156227A Division JP2015214576A (ja) 2009-07-15 2015-08-06 アセトアミノフェンの治療効果を改善するためのｎ‐アセチルシステイン組成物および方法

Publications (2)

Publication Number Publication Date
JP2012533559A true JP2012533559A (ja) 2012-12-27
JP2012533559A5 JP2012533559A5 (US07981874-20110719-C00313.png) 2013-09-05

Family

ID=43449800

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012520791A Pending JP2012533559A (ja) 2009-07-15 2010-07-15 アセトアミノフェンの治療効果を改善するためのｎ−アセチルシステイン組成物および方法
JP2015156227A Pending JP2015214576A (ja) 2009-07-15 2015-08-06 アセトアミノフェンの治療効果を改善するためのｎ‐アセチルシステイン組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015156227A Pending JP2015214576A (ja) 2009-07-15 2015-08-06 アセトアミノフェンの治療効果を改善するためのｎ‐アセチルシステイン組成物および方法

Country Status (6)

Country Link
US (1) US20110014285A1 (US07981874-20110719-C00313.png)
EP (1) EP2453743B1 (US07981874-20110719-C00313.png)
JP (2) JP2012533559A (US07981874-20110719-C00313.png)
CN (2) CN102573463A (US07981874-20110719-C00313.png)
CA (1) CA2767833C (US07981874-20110719-C00313.png)
WO (1) WO2011008976A1 (US07981874-20110719-C00313.png)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018503689A (ja) * 2015-01-27 2018-02-08 フローレンゲイル・エル・エル・シー 治癒性局所用組成物

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130296430A1 (en) * 2012-05-03 2013-11-07 Antonio Hardan Compositions and methods for treating autism and autism spectrum disorder
US8747894B2 (en) * 2012-05-08 2014-06-10 Alpex Pharma S.A. Effervescent compositions containing N-acetylcysteine
WO2015148800A1 (en) 2014-03-26 2015-10-01 Nanovis, LLC Anti-microbial device and method for its manufacture
EP3302456A4 (en) * 2015-06-05 2018-12-19 Glenn A. Goldstein Use of n-acetylcysteine amide in the treatment of acetaminophen overdose
WO2017136775A1 (en) * 2016-02-04 2017-08-10 Czap Research And Development, Llc Controlled-release and stratified cyclodextrin inclusion complex vehicles
CN110214004B (zh) 2017-01-24 2022-11-22 株式会社优盛制药 含有对乙酰氨基酚的注射剂组合物
US11389409B2 (en) * 2019-08-30 2022-07-19 Remedy Diagnostics LLC Transdermal device comprising acetaminophen prodrug
US11413238B2 (en) 2020-02-18 2022-08-16 Endo Ventures Limited N-acetylcysteine compositions and methods
EP4238559A1 (en) * 2022-03-04 2023-09-06 Centre Hospitalier Universitaire de Caen Normandie Combinations of acetaminophen and n-acetyl cysteine for the treatment of pain and fever

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11514013A (ja) * 1996-08-05 1999-11-30 エスセーエール ファルマトップ 新規なパラセタモールの安定な液体配合物とその製造方法
JP2005508840A (ja) * 2001-03-30 2005-04-07 バイオアドヴァンテックス ファーマ インコーポレイテッド Ｎ−アセチルシステイン組成物及び薬剤毒性治療または防止方法
WO2008073344A1 (en) * 2006-12-09 2008-06-19 Soderling Eric M Acetaminophen compositions having minimized side effects including reduced hepatotoxicity
WO2009064928A1 (en) * 2007-11-13 2009-05-22 Cadence Pharmaceuticals Reduced dose intravenous acetaminophen

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4127645A (en) * 1976-05-21 1978-11-28 Life Savers, Inc. Effervescent tablet and method
US4314989A (en) * 1980-05-07 1982-02-09 Rosen Gerald M Methionine sulfoxide amflioration of acetaminophen toxicity
US5474757A (en) 1992-10-16 1995-12-12 Rutgers University Prevention of acetaminophen overdose toxicity with organosulfur compounds
GB9305058D0 (en) * 1993-03-12 1993-04-28 Penn Pharm Ltd Pharmaceutical compositions
DE29707005U1 (de) 1997-04-18 1997-06-26 Klinge Pharma GmbH, 81673 München Stabilisiertes Arzneimittel enthaltend Cysteinylderivate
IT1311907B1 (it) * 1999-04-06 2002-03-20 Zambon Spa Compresse deglutibili ad alto contenuto di n-acetilcisteina.
WO2001068069A2 (en) 2000-03-15 2001-09-20 King's College London Pharmaceutical composition comprising paracetamol
WO2006069293A2 (en) * 2004-12-22 2006-06-29 Friedman Robert S Composition comprising n-acetylcysteine and further pain or anti- inflamm medications
US8148356B2 (en) * 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
US20080226715A1 (en) * 2007-03-16 2008-09-18 Albert Cha Therapeutic compositions and methods

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11514013A (ja) * 1996-08-05 1999-11-30 エスセーエール ファルマトップ 新規なパラセタモールの安定な液体配合物とその製造方法
JP2005508840A (ja) * 2001-03-30 2005-04-07 バイオアドヴァンテックス ファーマ インコーポレイテッド Ｎ−アセチルシステイン組成物及び薬剤毒性治療または防止方法
WO2008073344A1 (en) * 2006-12-09 2008-06-19 Soderling Eric M Acetaminophen compositions having minimized side effects including reduced hepatotoxicity
JP2010513229A (ja) * 2006-12-09 2010-04-30 エム． ソダーリング、エリック 軽減された肝毒性を含む最小限に抑制された副作用を有するアセトアミノフェン組成物
WO2009064928A1 (en) * 2007-11-13 2009-05-22 Cadence Pharmaceuticals Reduced dose intravenous acetaminophen
JP2011503198A (ja) * 2007-11-13 2011-01-27 ケイデンス ファーマシューティカルズ，インク． 低用量静脈内アセトアミノフェン

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6014034329; 中毒研究 ２１（４）, 20081025, ３６１-３６６ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018503689A (ja) * 2015-01-27 2018-02-08 フローレンゲイル・エル・エル・シー 治癒性局所用組成物

Also Published As

Publication number Publication date
CN102573463A (zh) 2012-07-11
CA2767833A1 (en) 2011-01-20
CN105687177A (zh) 2016-06-22
EP2453743A1 (en) 2012-05-23
US20110014285A1 (en) 2011-01-20
WO2011008976A1 (en) 2011-01-20
JP2015214576A (ja) 2015-12-03
EP2453743B1 (en) 2017-04-12
CA2767833C (en) 2018-10-23
EP2453743A4 (en) 2012-12-26

Similar Documents

Publication Publication Date Title
JP2015214576A (ja) アセトアミノフェンの治療効果を改善するためのｎ‐アセチルシステイン組成物および方法
US8349359B2 (en) Liposomal formulation for oral administration of glutathione (reduced)
ES2395555T3 (es) Formulación liposomal para la administración oral de glutatión (reducido)
US20030119909A1 (en) Stabilized medicament containing cysteinyl derivatives
WO2014070769A1 (en) Methods and compositions for treating mucosal tissue disorders
JP6511492B2 (ja) 女性胃不全麻痺に関係する症状の処置
ES2954361T3 (es) Métodos de uso de dipivefrina
JP5542309B2 (ja) 経口医薬組成物
JP5529165B2 (ja) 脂質低下薬を経口腔粘膜投与する処方物（ｆｏｒｍｕｌａｔｉｏｎ）
KR20070034576A (ko) 록소프로펜을 함유하는 경구 투여용 조성물
Lee et al. Drug dosages
US20050043274A1 (en) Pharmaceutical compositions and methods for lowering blood pressure and pulse rate
US20210369648A1 (en) Cysteamine zinc complex and method of using a cysteamine zinc complex
ES2935684T3 (es) Formulaciones de epinefrina intranasales y métodos para el tratamiento de enfermedades
JP4444721B2 (ja) 医薬組成物
CA3213365A1 (en) Prevention and treatment of coronavirus infection

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130716

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130716

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140813

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141112

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141119

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150213

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150406